Bionexus Gene Lab Stock Current Ratio
| BGLC Stock | USD 0.25 0.04 13.79% |
BioNexus Gene Lab fundamentals help investors to digest information that contributes to BioNexus Gene's financial success or failures. It also enables traders to predict the movement of BioNexus Stock. The fundamental analysis module provides a way to measure BioNexus Gene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNexus Gene stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 4.93 | 7.15 |
BioNexus | Current Ratio |
BioNexus Gene Lab Company Current Ratio Analysis
BioNexus Gene's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current BioNexus Gene Current Ratio | 3.84 X |
Most of BioNexus Gene's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNexus Gene Lab is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioNexus Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for BioNexus Gene is extremely important. It helps to project a fair market value of BioNexus Stock properly, considering its historical fundamentals such as Current Ratio. Since BioNexus Gene's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioNexus Gene's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioNexus Gene's interrelated accounts and indicators.
Click cells to compare fundamentals
BioNexus Current Ratio Historical Pattern
Today, most investors in BioNexus Gene Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioNexus Gene's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of BioNexus Gene current ratio as a starting point in their analysis.
BioNexus Gene Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
BioNexus Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, BioNexus Gene Lab has a Current Ratio of 3.84 times. This is 31.96% higher than that of the Chemicals sector and 13.9% lower than that of the Materials industry. The current ratio for all United States stocks is 77.78% lower than that of the firm.
BioNexus Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNexus Gene's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNexus Gene could also be used in its relative valuation, which is a method of valuing BioNexus Gene by comparing valuation metrics of similar companies.BioNexus Gene is currently under evaluation in current ratio category among its peers.
BioNexus Gene Current Valuation Drivers
We derive many important indicators used in calculating different scores of BioNexus Gene from analyzing BioNexus Gene's financial statements. These drivers represent accounts that assess BioNexus Gene's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioNexus Gene's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 35.4M | 236.8M | 364.8M | 164.3M | 8.4M | 8.0M | |
| Enterprise Value | 34.6M | 234.1M | 362.8M | 162.2M | 2.6M | 2.5M |
BioNexus Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 581.28 K | ||||
| Shares Outstanding | 17.97 M | ||||
| Shares Owned By Insiders | 43.72 % | ||||
| Shares Owned By Institutions | 0.87 % | ||||
| Number Of Shares Shorted | 140.38 K | ||||
| Price To Earning | 350.00 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 0.49 X | ||||
| Revenue | 9.77 M | ||||
| Gross Profit | 2.19 M | ||||
| EBITDA | (2.49 M) | ||||
| Net Income | (2.63 M) | ||||
| Cash And Equivalents | 1.34 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 133.4 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 3.84 X | ||||
| Book Value Per Share | 0.55 X | ||||
| Cash Flow From Operations | (1.3 M) | ||||
| Short Ratio | 2.21 X | ||||
| Earnings Per Share | (0.06) X | ||||
| Number Of Employees | 30 | ||||
| Beta | 1.87 | ||||
| Market Capitalization | 4.49 M | ||||
| Total Asset | 11.4 M | ||||
| Retained Earnings | (1.84 M) | ||||
| Working Capital | 6.42 M | ||||
| Net Asset | 11.4 M |
About BioNexus Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNexus Gene Lab's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNexus Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNexus Gene Lab based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:Check out BioNexus Gene Piotroski F Score and BioNexus Gene Altman Z Score analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.06) | Revenue Per Share 0.526 | Quarterly Revenue Growth (0.23) | Return On Assets (0.10) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.